Advertisement

Young Patients with Breast Cancer

  • P. A. Francis
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Among women diagnosed with early breast cancer, one in four will be premenopausal. In relation to breast cancer, the term “young” typically refers to patients aged less than 40 years. While breast cancer in young women is not common, breast cancer remains the leading cause of cancer deaths among young women. Only about 1 in 40 women diagnosed with breast cancer will be very young (defined here as <35 years).

Keywords

Breast Cancer Premenopausal Woman Aromatase Inhibitor Early Breast Cancer Premature Ovarian Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. NEJM. 1986;315:559–63.PubMedCrossRefGoogle Scholar
  2. 2.
    De la Rochefordiere A, Asselain B, Campana F, et al. Age as a prognostic factor in premenopausal breast cancer. Lancet. 1993;341;1039–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Albain K, Allred C, Clark G. Breast cancer outcome and predictors of outcome: Are there age differentials? JNCI monographs. 1994;16:35–42.Google Scholar
  4. 4.
    Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497–503.PubMedCrossRefGoogle Scholar
  5. 5.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting Highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  7. 7.
    Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor positive breast cancer? Lancet. 2000;355:1869–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. JNCI Monographs. 2001;30:44–51.CrossRefGoogle Scholar
  9. 9.
    Pagani O, O’Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34:632–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effect of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1990;1:183–8.PubMedGoogle Scholar
  11. 11.
    Tancini G, Valagussa P, Bajetta E, et al. Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials. 1979;2:285–92.PubMedGoogle Scholar
  12. 12.
    Cobleigh M et al. Proc Am Soc Clin Oncol. 1995;14:A158.Google Scholar
  13. 13.
    Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.PubMedGoogle Scholar
  14. 14.
    Davidson N, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results form INT 0101 (E5188). J Clin Oncol. 2005;23:5973–82.PubMedCrossRefGoogle Scholar
  15. 15.
    International Breast Cancer Study Group. Adjuvant Chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. JNCI. 2003;95:1833–46.Google Scholar
  16. 16.
    Love RR, Nguyen BD, Nguyen VD, et al. Young age as an adverse prognostic factor in premenopausal women with operable breast cancer. Clin Breast Cancer. 2002;2:294–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bartelink H, Horiot JC, Poortmans P, et al. Impact of radiation dose on local control, fibrosis and survival after breast conserving treatment:10 year results of the EORTC Trial 22881-10882. Breast Cancer Res and Treat. 2006;100(suppl 1, S8).Google Scholar
  18. 18.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of radiation and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of randomised trials. Lancet. 2005;366:2087–106.Google Scholar
  19. 19.
    Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Guinee VF, Olsson H, Moller T, et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994;343:1587–1589.PubMedCrossRefGoogle Scholar
  21. 21.
    Phillips KA, Milne RL, Friedlander ML, et al. Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol. 2004;22:699–705.PubMedCrossRefGoogle Scholar
  22. 22.
    Dite GS, Jenkins MA, Hocking JS, et al. Familial risks, early onset breast cancer, and BRCA1 and BRCA2 germline mutations. JNCI. 2003;95:448–57.PubMedGoogle Scholar
  23. 23.
    Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: Reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • P. A. Francis
    • 1
  1. 1.Breast Medical OncologyPeter MacCallum Cancer CenterMelbourneAustralia

Personalised recommendations